Advanced Solid Tumor Clinical Trials

262 recruiting

Advanced Solid Tumor Trials at a Glance

520 actively recruiting trials for advanced solid tumor are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Phase 1 with 464 trials, with the heaviest enrollment activity in Houston, Shanghai, and San Antonio. Lead sponsors running advanced solid tumor studies include BeOne Medicines, Jiangsu HengRui Medicine Co., Ltd., and MediLink Therapeutics (Suzhou) Co., Ltd..

Browse advanced solid tumor trials by phase

Treatments under study

About Advanced Solid Tumor Clinical Trials

Looking for clinical trials for Advanced Solid Tumor? There are currently 262 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 520 trials

Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Advanced Solid TumorMetastatic Solid Tumor
Ipsen102 enrolled11 locationsNCT07213830
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Metastatic Solid TumorLocally Advanced Solid Tumor
Ipsen114 enrolled12 locationsNCT07213817
Recruiting
Phase 1Phase 2

Study in Advanced Solid Tumor Patients

Advanced Solid Tumor
Callio Therapeutics306 enrolled11 locationsNCT07300943
Recruiting
Phase 1Phase 2

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Advanced Solid Tumor
Ipsen85 enrolled13 locationsNCT06833008
Recruiting
Early Phase 1

NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors

Advanced Solid Tumors
Base Therapeutics (Shanghai) Co., Ltd.18 enrolled1 locationNCT07561437
Recruiting
Phase 1Phase 2

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd181 enrolled12 locationsNCT05898399
Recruiting
Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Gastric CancerAdvanced Solid TumorNon-small Cell Lung Cancer+4 more
AstraZeneca70 enrolled15 locationsNCT06147037
Recruiting
Phase 1Phase 2

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.198 enrolled1 locationNCT07298772
Recruiting
Phase 1Phase 2

HEC169096 in Participants With Advanced Solid Tumors

Advanced Solid Tumor
Sunshine Lake Pharma Co., Ltd.456 enrolled1 locationNCT05451602
Recruiting
Phase 1Phase 2

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting
Phase 1

Safety of AM-928 Infusion in Advanced Solid Tumors

Advanced Solid Tumor
AcadeMab Biomedical Inc.38 enrolled1 locationNCT05687682
Recruiting
Phase 1Phase 2

A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Advanced Solid Tumors
Chong Kun Dang Pharmaceutical140 enrolled1 locationNCT07439094
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1

A Study of MGC028 in Participants With Advanced Solid Tumors

CholangiocarcinomaColorectal CarcinomaPancreatic Carcinoma+2 more
MacroGenics124 enrolled7 locationsNCT06723236
Recruiting
Phase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

Prostate CancerMelanomaSmall Cell Lung Cancer+1 more
Hangzhou DAC Biotechnology Co., Ltd.150 enrolled3 locationsNCT07177937
Recruiting
Phase 1

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Advanced Solid Tumor
Senhwa Biosciences, Inc.52 enrolled8 locationsNCT04890613
Recruiting
Phase 1

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.77 enrolled5 locationsNCT07166601
Recruiting
Phase 1

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

Advanced Solid Tumor
BeOne Medicines84 enrolled3 locationsNCT07414836
Recruiting
Phase 1

HWS116 Monotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company56 enrolled1 locationNCT07413328
Recruiting
Phase 1

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Advanced Solid Tumor
BeOne Medicines168 enrolled52 locationsNCT06625593